CD4 and cancer: The overall performance, discrimination, and calibration of the prediction model were evaluated.<h4>Results</h4>Eleven predictors were included in the final predictive model: sindillizumab, number of ≥2 underlying diseases, history of lung diseases, tirelizumab, non-small cell lung cancer (NSCLC), percentage of CD4<sup>+</sup> lymphocytes, body temperature, KPS score ≤70, hemoglobin, cancer stage IV, and history of antitumor therapy.